Advanced Therapy Medicinal Products - Market Insights, Competitive Landscape, and Market Forecast - 2032

Advanced Therapy Medicinal Products Market by Type (Gene-Therapy Medicines, Cell Therapy Medicines, Tissue Engineered Products, Combined ATMPs), Indication (Oncology, Cardiology, Neurology, Genetic Disorders, Infectious Diseases, Metabolic Disease, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the growing prevalence of chronic disease and rising number of genetic disease and cancer cases

The advanced therapy medicinal products (ATMP) market was valued at USD 30,778.72 million in 2024, growing at a CAGR of 14.17% during the forecast period from 2025 to 2032. The growth of the advanced therapy medicinal products market is mainly driven by the growing prevalence of chronic diseases. The rising number of genetic diseases, and cancer cases, increasing R&D activities, and partnerships among key players are key factors responsible for contributing to the positive growth of the advanced therapy medicinal products market during the forecast period from 2025 to 2032.

Advanced Therapy Medicinal Products Market Dynamics:

According to the data published by the Centers for Disease Control and Prevention (CDC) in February 2024, an estimated 129 million people were suffering from at least 1 major chronic disease such as heart disease, cancer, diabetes, obesity, and hypertension in the United States as of 2024.

Cancer is a major chronic disease affecting people around the world. The study conducted by the International Agency for Research on Cancer in December 2020, mentioned that an estimated 19.3 million new cancer cases were reported in 2020 across the globe. Cell therapy is used in cancer immunotherapy which uses the immune cells of the body to destroy cancer cells effectively. Thereby, the rising prevalence of chronic diseases such as cancer which is creating the demand for cell and gene therapy is expected to drive the market growth.

A report by the World Economic Forum published in February 2023, stated that approximately 475 million individuals were living with genetic rare conditions in 2021 across the globe. Within the upcoming five years, it was anticipated that around 15.2 million people were expected to undergo clinical genomic testing specifically aimed at identifying rare conditions. Gene therapy is developed to correct or replace abnormal genes with healthy ones to cure diseases or enhance the body's ability to combat them. Thus, the rising number of genetic disease cases is expected to propel the market growth.

Key players in the market are establishing research partnerships for the development of precision cell and gene therapies for the treatment of chronic diseases such as cancer and neurodegenerative diseases. For instance, in April 2021, Spark Therapeutics announced a research collaboration with Senti Biosciences to enhance its gene therapy research. The collaboration integrates Senti Bio's advanced gene circuit technology platform and expertise in high-throughput synthetic promoter design with Spark Therapeutics' investigational gene therapies targeting the central nervous system, eye, or liver. Such research collaborations to develop advanced gene therapies are expected to boost market expansion.

However, the high cost of cell and gene therapies, and the safety concerns associated with advanced therapy medicinal products, among others are some of the key constraints that may hinder the growth of the advanced therapy medicinal products market.

Advanced Therapy Medicinal Products Market Segment Analysis:

Advanced Therapy Medicinal Products Market by Type (Gene-Therapy Medicines, Cell Therapy Medicines, Tissue Engineered Products, Combined ATMPs), Indication (Oncology, Cardiology, Neurology, Genetic Disorders, Infectious Diseases, Metabolic Disease, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the type segment, the cell therapy medicines category is estimated to account for the largest market share in the advanced therapy medicinal products market in 2024 due to the potential of cell therapies to transform disease treatment. Cell therapy is an innovative medical approach involving the introduction of viable and functional cells into a patient's body to enhance or replace damaged tissues, particularly beneficial when cell dysfunction or loss plays a crucial role in the progression of a specific disease. Cell therapies have shown success due to which key players are working in this area to develop next-generation programmed cell therapies for the treatment of various diseases such as cancer. For instance, in February 2024, BioNTech announced its partnership with Autolus Therapeutics to develop and commercialization of cell therapies. This strategic collaboration aimed at advancing both companies' autologous CAR-T programs for the treatment of multiple cancer indications.

CAR-T cell therapy exemplifies this personalized approach where a patient's T cells are extracted, genetically modified, activated, expanded, purified, and then reintroduced into the patient's body. Such advantages have boosted the research activities made by key players in this area. In March 2024, Bristol-Myers Squibb Company announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Breyanzi(R) (lisocabtagene maraleucel; liso-cel), a CD19-directed CAR T cell therapy, for treating adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Further, cell therapy leverages the body's natural systems such as the cellular immune system and the capacity to repair or replace faulty genes making them preferred choices for personalized medicine. Therefore, the growing use and development of cell therapies, including stem cell therapy, CAR-T cell therapy, and tissue engineering contribute to the growth of the segment, thereby driving the growth of the advanced therapy medicinal products market during the forecast period.

North America Is Expected To Dominate The Overall Advanced Therapy Medicinal Products Market:

North America is expected to account for the largest market share of the advanced therapy medicinal products market in 2024. This can be attributed to the rising number of cancer cases and the rise in the R&D activities by key players in the region, thus driving the growth of the advanced therapy medicinal products market in North America.

According to the American Cancer Society's Cancer Facts & Figures published in 2024, nearly 2 million new cancer cases were expected to be diagnosed in the United States in 2024, up from 1.9 million in 2023. Cell therapy genetically modifies a patient's cells to express a particular receptor that targets cancer cells. These altered cells are then injected into the patient's body, where they can identify tumor antigens and destroy cancer cells expressing the targeted antigen. Therefore, the rising cancer cases that create demand for advanced therapies will drive market growth.

The data published by the National Cancer Institute in May 2024 indicated that there were an estimated 18.1 million cancer patients in the United States in 2022 and this number of cancer patients is expected to increase reaching 22.5 million by 2032 and 26 million by 2040.

Rising R&D activities of key players in the region to innovative advanced therapy medicinal products for the treatment of chronic diseases are contributing to the positive growth of the market. For instance, in February 2022, Janssen Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved CARVYKTI (ciltacabtagene autoleucel; cilta-cel) for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). CARVYKTI(TM) is a type of CAR-T therapy that utilizes two single-domain antibodies targeting B-cell maturation antigen (BCMA). Therefore, the rising number of cancer cases and surge in R&D activities by key players in the region is expected to propel the growth of North America advanced therapy medicinal products market.

Advanced Therapy Medicinal Products Market Key Players:

Some of the key market players operating in the advanced therapy medicinal products market include Pfizer Inc., Novartis AG, Gilead Sciences, Inc., Kolon TissueGene, Inc., Bluebird Bio, Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Organogenesis Inc., BioNTech, Regeneron Pharmaceuticals Inc., ALLOGENE THERAPEUTICS, CRISPR Therapeutics, Autolus Therapeutics, Anixa Biosciences, Inc., Amgen Inc., Intellia Therapeutics, Inc., Adaptimmune, Voyager Therapeutics Inc., Sangamo Therapeutics, Inc., Biogen, and others.

Recent Developmental Activities in the Advanced Therapy Medicinal Products Market:

• In April 2024, Pfizer Inc. announced that it received US FDA approval for BEQVEZ (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B. BEQVEZ is an adeno-associated virus (AAV)-based one-time treatment gene therapy developed for patients suffering from hemophilia B.
• In February 2024, BioNTech and Autolus Therapeutics announced a strategic collaboration to develop CAR-T cell therapy aimed at advancing their pipeline and expanding late-stage programs. Through this partnership, both companies focused on accelerating pipeline programs to develop advanced therapies for multiple cancer indications.
• In January 2022, Fate Therapeutics announced that it received FDA clearance for an Investigational New Drug (IND) application for FT536. FT536 is a chimeric antigen receptor (CAR) NK cell product candidate for the treatment of advanced solid tumors.
• In June 2022, Bristol Myers Squibb announced that the FDA approved Breyanzi (lisocabtagene maraleucel). Breyanzi is a chimeric antigen receptor (CAR) T-cell therapy for the treatment of adult patients with large B-cell lymphoma (LBCL) and other lymphatic cancers.

Key Takeaways from the Advanced Therapy Medicinal Products Market Report Study

• Market size analysis for current Advanced Therapy Medicinal Products Market size (2024), and market forecast for 8 years (2025 to 2032)
• Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
• Key companies dominating the global Advanced Therapy Medicinal Products market.
• Various opportunities available for the other competitors in the Advanced Therapy Medicinal Products Market space.
• What are the top-performing segments in 2024? How these segments will perform in 2032?
• Which are the top-performing regions and countries in the current Advanced Therapy Medicinal Products market scenario?
• Which are the regions and countries where companies should have concentrated on opportunities for Advanced Therapy Medicinal Products market growth in the coming future?

Target Audience who can be benefited from this Advanced Therapy Medicinal Products Market Report Study

• Advanced Therapy Medicinal Products product providers
• Research organizations and consulting companies
• Advanced Therapy Medicinal Products related organizations, associations, forums, and other alliances
• Government and corporate offices
• Start-up companies, venture capitalists, and private equity firms
• Distributors and Traders dealing in Advanced Therapy Medicinal Products
• Various end-users who want to know more about the Advanced Therapy Medicinal Products Market and the latest technological developments in the Advanced Therapy Medicinal Products Market.

Frequently Asked Questions for the Advanced Therapy Medicinal Products Market:

1. What are Advanced Therapy Medicinal Products?

• Advanced Therapy Medicinal Products are innovative therapeutic drugs that utilize advanced technologies to manipulate cells, tissues, or genes for the purpose of diagnosis, prevention and treatment of chronic diseases.

2. What is the market for Advanced Therapy Medicinal Products?

• The advanced therapy medicinal products (ATMP) market was valued at USD 30,778.72 million in 2024, growing at a CAGR of 14.17% during the forecast period from 2025 to 2032.

3. What are the drivers for the global Advanced Therapy Medicinal Products market?

• The advanced therapy medicinal products market is expected to grow at a rapid pace due to the increasing prevalence of chronic diseases. Factors such as the rising occurrences of genetic diseases and cancers, along with increasing research and development initiatives and collaborations among major industry players, are pivotal in driving the growth of the market during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global Advanced Therapy Medicinal Products market?)

• Some of the key market players operating in the advanced therapy medicinal products market include Pfizer Inc., Novartis AG, Gilead Sciences, Inc., Kolon TissueGene, Inc., Bluebird Bio, Inc., F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Organogenesis Inc., BioNTech, Regeneron Pharmaceuticals Inc., ALLOGENE THERAPEUTICS, CRISPR Therapeutics, Autolus Therapeutics, Anixa Biosciences, Inc., Amgen Inc., Intellia Therapeutics, Inc., Adaptimmune, Voyager Therapeutics Inc., Sangamo Therapeutics, Inc., Biogen, and others.

5. Which region has the highest share in the global Advanced Therapy Medicinal Products market?

• North America is expected to account for the largest market share of the advanced therapy medicinal products market in 2024. This can be attributed to the rising number of cancer cases and the rise in the R&D activities by key players in the region, thus driving the growth of the advanced therapy medicinal products market in North America.